Next-generation sequencing to identify mutations that may predict outcome after allogeneic stem cell transplantation for AML.
Marlise R. Luskin(Dana-Farber Cancer Institute), Ran Reshef(Abramson Cancer Center), James K. Mangan(UC San Diego Health System), Robert Daber(University of Pennsylvania), Jennifer J.D. Morrissette(University of Pennsylvania), Edward A. Stadtmauer(University of Pennsylvania), Martin Carroll(University of Pennsylvania), Alexander E. Perl(University of Pennsylvania), Alison W. Loren(University of Pennsylvania), David L. Porter(Chapman University), Noelle V. Frey(Hospital of the University of Pennsylvania), Adam Bagg(University of Pennsylvania), Selina M. Luger(University of Pennsylvania), Elizabeth O. Hexner(University of Pennsylvania), Caroline E. Sloan(University of Pennsylvania)
Cited by 1
Related Papers
ASTCT Consensus Grading for Cytokine Release Syndrome and Neurologic Toxicity Associated with Immune Effector Cells
|Transplantation and Cellular Therapy|2018|3.6k
International Consensus Classification of Myeloid Neoplasms and Acute Leukemias: integrating morphologic, clinical, and genomic data
|Blood|2022|2.8k
Prognostic Relevance of Integrated Genetic Profiling in Acute Myeloid Leukemia
|New England Journal of Medicine|2012|1.9k
Gilteritinib or Chemotherapy for Relapsed or Refractory <i>FLT3</i> -Mutated AML
|New England Journal of Medicine|2019|1.3k
Lenalidomide after Stem-Cell Transplantation for Multiple Myeloma
|New England Journal of Medicine|2012|1.2k